Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) France

Research

Date range: 1 August 2022 - 31 July 2023

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) published between 1 August 2022 - 31 July 2023 which are tracked by the Nature Index.

Hover over the donut graph to view the Share for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

Article Count and Share for Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)
Count Share
9 0.76

Outputs by subject (Share)

Outputs by subject
Subject Count Share
4 0.59
5 0.17

Share output for the past 5 years

Share per year
2018 2019 2020 2021 2022*
0.00 0.00 0.45 0.28 1.57

Compare Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) with other institutions

*Note: 2022 data contains Share for article affiliations from newly added health-science journals.

Nature Strategy Reports

Nature Strategy Reports gives you simple insights to support decisions that impact your organisation

The reports created for you by our subject matter experts combine compelling insights with Nature’s trust and authority. Get an in-depth analysis of your and your peers’ research performance, including a breakdown of relative strengths and weaknesses. All of which is crafted using data and tools from across Nature Research Intelligence, covering all major disciplines and all regions of the world.

Get started

Collaboration

Date range: 1 August 2022 - 31 July 2023

International vs. domestic collaboration by Share

  • 85.24% Domestic (106 institutions)
  • 14.76% International (54 institutions)

Hover over the graph to view the percentage of collaboration.

Top 10 domestic collaborators with Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) by Share*

  1. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and French National Centre for Scientific Research (CNRS) (1.90)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.76
    French National Centre for Scientific Research (CNRS)1.14
  2. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and University of Lille Nord de France (1.77)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.76
    University of Lille Nord de France1.01
  3. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Centre Hospitalier Universitaire de Lille (CHU Lille) (1.33)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.76
    Centre Hospitalier Universitaire de Lille (CHU Lille)0.57
  4. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and National Institute for Health and Medical Research (INSERM) (1.22)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.76
    National Institute for Health and Medical Research (INSERM)0.47
  5. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Unité de Glycobiologie Structurale et Fonctionnelle (UGSF) (1.15)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)
    Unité de Glycobiologie Structurale et Fonctionnelle (UGSF)1.02
  6. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Pasteur Institute (0.96)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.76
    Pasteur Institute0.20
  7. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Institut Jacques Monod (IJM) (0.96)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)
    Institut Jacques Monod (IJM)0.88
  8. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Centre Oscar Lambret (0.89)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.76
    Centre Oscar Lambret
  9. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Risk Factors and Molecular Determinants of Aging-related Diseases (RID-AGE) (0.68)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.39
    Risk Factors and Molecular Determinants of Aging-related Diseases (RID-AGE)0.29
  10. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Paris Cité University (0.67)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.17
    Paris Cité University0.49

Top 10 international collaborators with Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) by Share*

  1. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and AstraZeneca plc (0.72)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)
    AstraZeneca plc0.67
  2. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Harvard University (0.66)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)
    Harvard University0.62
  3. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Michigan State University (MSU) (0.50)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.36
    Michigan State University (MSU)
  4. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and University of Coimbra (UC) (0.39)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)0.36
    University of Coimbra (UC)
  5. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Broad Institute of MIT and Harvard (0.23)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)
    Broad Institute of MIT and Harvard0.19
  6. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and University of Gothenburg (GU) (0.22)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)
    University of Gothenburg (GU)
  7. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Ramsay Health Care (0.16)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)
    Ramsay Health Care
  8. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Massachusetts Institute of Technology (MIT) (0.14)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)
    Massachusetts Institute of Technology (MIT)
  9. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Amsterdam UMC (0.11)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)
    Amsterdam UMC
  10. Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) and Imperial College London (ICL) (0.11)
    Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER)
    Imperial College London (ICL)

*Share is the fractional count allocated to an institution for an article that takes into account the percentage of authors from that institution and the number of affiliated institutions that contributed to the article. The horizontal stacked bar charts above indicate the Share contributed by each institution in the bilateral collaboration. If the Share is not shown, hover over the bar to display it.

Nature Careers

Need to hire scientific researchers?

Nature Careers is visited by over 180,000 active jobseekers per month that you can target directly with your role. Application response rates have increased by 28% on average over 2022 averages.

Relationships

Partner Institutions

Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) is a research collaboration whose article contributions are accrued to its participating partner institutions below.


Numerical information only is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.